Taysha Gene Therapies, INC. (TSHA) — SEC Filings

Overview

Taysha Gene Therapies, INC. (TSHA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 22, 2026: Taysha Gene Therapies, Inc. filed its Annual Report to Security Holders (ARS) on April 22, 2026, for the period ending December 31, 2025. The company is based in Dallas, Texas, and operates in the biological products sector. This filing provides a comprehensive overview of the company's performance

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Taysha Gene Therapies, INC. is neutral.

Filing Type Overview

Taysha Gene Therapies, INC. (TSHA) has filed 1 ARS, 1 DEFA14A, 17 8-K, 5 10-Q, 1 8-K/A, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 4 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• Taysha Gene Therapies Files 2025 Annual Report — ARS · Apr 22, 2026 Risk: medium
  Taysha Gene Therapies, Inc. filed its Annual Report to Security Holders (ARS) on April 22, 2026, for the period ending December 31, 2025. The company is based i
• Taysha Gene Therapies Files DEFA14A Proxy Materials — DEFA14A · Apr 22, 2026 Risk: low
  Taysha Gene Therapies, Inc. filed a DEFA14A on April 22, 2026, related to additional definitive proxy soliciting materials. The filing includes standard DEFA14A
• Taysha Gene Therapies Files 8-K on Agreements and Financials — 8-K · Nov 4, 2025 Risk: medium
  Taysha Gene Therapies, Inc. filed an 8-K on November 4, 2025, reporting on the entry into a material definitive agreement, results of operations, and financial
• Taysha Gene Therapies Files 8-K — 8-K · Oct 16, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on October 16, 2025, reporting other events and financial statements. The filing details the company's principal execut
• Taysha Gene Therapies Files 8-K — 8-K · Oct 9, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on October 9, 2025, reporting other events and financial statements. The company, incorporated in Delaware with its pri
• Taysha Gene Therapies Files 8-K — 8-K · Oct 2, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on October 2, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is involved
• Taysha Gene Therapies Files 8-K on Financials — 8-K · Aug 12, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Taysha Gene Therapies' Net Loss Widens Amid Increased R&D Spend — 10-Q · Aug 12, 2025 Risk: high
  Taysha Gene Therapies, Inc. (TSHA) reported a net loss of $26.88 million for the three months ended June 30, 2025, an increase from a net loss of $20.93 million
• Taysha Gene Therapies Files 8-K on Corporate Matters — 8-K · Jun 3, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on June 3, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing indi
• Taysha Gene Therapies Files 8-K/A Amendment — 8-K/A · May 29, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K/A amendment on May 29, 2025, related to events reported on May 28, 2025. The filing primarily concerns Regulation FD Di
• Taysha Gene Therapies Files 8-K — 8-K · May 28, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 28, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
• Taysha Gene Therapies Files 8-K on Financials — 8-K · May 15, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Taysha Gene Therapies Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Taysha Gene Therapies, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31. Key dates mentioned include Apri
• Taysha Gene Therapies Files 2025 Proxy Statement — DEF 14A · Apr 21, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed its definitive proxy statement on April 21, 2025, for its annual meeting on June 2, 2025. The filing covers the fiscal year en
• Taysha Gene Therapies Files 8-K — 8-K · Feb 26, 2025 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition, as well as financial statements a
• 10-K Filing — 10-K · Feb 26, 2025
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Taysha Gene Therapies Files 8-K — 8-K · Nov 13, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, as well as financial statements a
• Taysha Gene Therapies Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  Taysha Gene Therapies, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the th
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G Filing — SC 13G · Oct 22, 2024
• Taysha Gene Therapies Files 8-K — 8-K · Aug 12, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Taysha Gene Therapies Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
  Taysha Gene Therapies, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business oper
• Astellas to Acquire Taysha Gene Therapies for $1.1 Billion — 8-K · Jun 26, 2024 Risk: medium
  Taysha Gene Therapies, Inc. announced on June 25, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Astellas Pharma Inc. f
• Taysha Gene Therapies Files 8-K — 8-K · Jun 18, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on June 18, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific
• Taysha Gene Therapies Files 8-K on Shareholder Vote Matters — 8-K · May 30, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 30, 2024, reporting on a submission of matters to a vote of security holders that occurred on May 29, 2024. The
• Taysha Gene Therapies Files 8-K — 8-K · May 14, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• Taysha Gene Therapies Q1 2024 Update — 10-Q · May 14, 2024 Risk: medium
  Taysha Gene Therapies, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported cash and cash equivalents of $129.5 million as of March 31
• Taysha Gene Therapies Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 18, 2024 Risk: low
  Taysha Gene Therapies, Inc. (TSHA) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. Annual Meeting scheduled for May 29, 2024, at 3:00 p.m. ET,
• Taysha Gene Therapies Files 8-K — 8-K · Mar 19, 2024 Risk: low
  Taysha Gene Therapies, Inc. filed an 8-K on March 19, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Taysha Gene Therapies Files 2023 Annual Report on Form 10-K — 10-K · Mar 19, 2024 Risk:
  Taysha Gene Therapies, Inc. (TSHA) filed a Annual Report (10-K) with the SEC on March 19, 2024. Taysha Gene Therapies, Inc. filed its 2023 Form 10-K on March 19
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• TCG Crossover GP I Reports 0% Stake in Taysha Gene Therapies — SC 13G/A · Feb 9, 2024 Risk: medium
  TCG Crossover GP I, LLC, a Delaware-based entity, has filed an amended SC 13G/A for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) as of December 31, 2023. This fil
• FMR LLC & Abigail Johnson Trim Taysha Gene Therapies Stake to 12.002% — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Taysha Gene Therapies, Inc. (TSHA) to 12.00
• Taysha Gene Therapies Files 8-K for Reg FD Disclosure — 8-K · Jan 10, 2024
  Taysha Gene Therapies, Inc. filed an 8-K on January 10, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates

Risk Profile

Risk Assessment: Of TSHA's 28 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Taysha Gene Therapies, INC.'s most recent 10-Q filing (Aug 12, 2025):

• Revenue: $1.99M
• Net Income: -$26.88M
• EPS: -$0.10
• Debt-to-Equity: N/A
• Cash Position: $312.76M
• Operating Margin: -1012.1%
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Sean Stalfort
• Alison Long, M.D., Ph.D.
• CHEN YU
• Abigail P. Johnson

Industry Context

The gene therapy sector is characterized by rapid innovation, high R&D costs, and significant regulatory scrutiny. TSHA operates in a competitive landscape with numerous players vying for breakthroughs in treating rare genetic diseases. Advancements in AAV vector technology and gene editing are key industry trends, but challenges remain in manufacturing scalability, long-term efficacy, and patient access.

Top Tags

8-K (6) · financial-reporting (6) · sec-filing (5) · financials (4) · 10-Q (4) · biotech (4) · gene-therapy (3) · SEC Filing (3) · Gene Therapy (3) · corporate-governance (3)

Key Numbers

• Fiscal Year End: 2025 — The period covered by the Annual Report to Security Holders.
• Filing Date: 2026-04-22 — The date Taysha Gene Therapies, Inc. submitted its ARS filing.
• SEC File Number: 001-39536 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 84-3199512 — Company's tax identification number.
• Net Loss (Q2 2025): $26.88M — Increased from $20.93M in Q2 2024
• Net Loss (YTD Q2 2025): $48.41M — Increased from $44.99M in YTD Q2 2024
• Net Proceeds from May 2025 Offering: $215.6M — Significantly boosted cash reserves
• Cash and Cash Equivalents (June 30, 2025): $312.76M — Up from $139.04M at Dec 31, 2024
• Accumulated Deficit (June 30, 2025): $650.7M — Reflects ongoing operating losses
• Research and Development Expenses (Q2 2025): $20.14M — Increased from $15.07M in Q2 2024
• Common Shares Outstanding (August 12, 2025): 272,794,885 — Increased due to public offering
• Offering Price per Share (May 2025): $2.75 — Price for common stock in public offering
• Period End Date: 20250331 — The financial information in this report pertains to this date.
• Reporting Period End Date: 2024-09-30 — Indicates the end of the fiscal quarter for which financial information is reported.
• Acquisition Price: $1.1B — Cash amount Astellas Pharma Inc. will pay for Taysha Gene Therapies, Inc.

Forward-Looking Statements

• {"claim":"Taysha Gene Therapies' stock price may experience short-term volatility due to the perceived lack of institutional confidence.","entity":"Taysha Gene Therapies, Inc.","targetDate":"Q2 2024","confidence":"medium"}
• {"claim":"Other institutional investors might re-evaluate their positions in Taysha Gene Therapies following this divestment.","entity":"Institutional Investors","targetDate":"Q3 2024","confidence":"low"}
• {"claim":"FMR LLC will likely maintain a significant, passive stake in Taysha Gene Therapies, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}

Related Companies

THSA

Frequently Asked Questions